RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07394387, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 70 years; sex: women only

    Registered eligibility fields

  2. Histologically confirmed invasive breast cancer, classified as Stage II-III triple-negative breast cancer (TNBC) according to the 8th edition AJCC TNM staging.

    Inclusion criterion 2

  3. Normal thyroid function (T3, T4, FT3, FT4, TSH).

    Inclusion criterion 20

  4. Major surgery within 4 weeks prior to study initiation or anticipated need for major surgery during the study.

    Exclusion criterion 6

  5. ECOG performance status of 0 or 1.

    Inclusion criterion 5

  6. Hemoglobin ≥90 g/L

    Inclusion criterion 7

    Platelet count ≥100×10\^9/L

    Inclusion criterion 9

    Absolute neutrophil count ≥1.5×10\^9/L

    Inclusion criterion 10

    AST and ALT ≤3× upper limit of normal (ULN)

    Inclusion criterion 11

    Total bilirubin ≤1.5× ULN

    Inclusion criterion 12

    Serum creatinine ≤1.5× ULN

    Inclusion criterion 13

  7. At least one measurable lesion as per RECIST v1.1 criteria.

    Inclusion criterion 3

  8. Concurrent other malignancies or history of other malignancies within the past 5 years (except adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix).

    Exclusion criterion 4

    HIV positive

    Exclusion criterion 12

    Active hepatitis B (HBV-DNA > 10\^3 IU/mL)

    Exclusion criterion 14

    Active hepatitis C (HCV antibody positive with detectable HCV-RNA)

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07394387, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Female patients aged ≥18 and ≤70 years.
  • Histologically confirmed invasive breast cancer, classified as Stage II-III triple-negative breast cancer (TNBC) according to the 8th edition AJCC TNM staging.
  • At least one measurable lesion as per RECIST v1.1 criteria.
  • No prior chemotherapy, immunotherapy, endocrine therapy, radical surgery, or radiotherapy for breast cancer.
  • ECOG performance status of 0 or 1.
  • Adequate organ function, defined as:
  • Hemoglobin ≥90 g/L
  • White blood cell count ≥3.5×10\^9/L
  • Platelet count ≥100×10\^9/L
  • Absolute neutrophil count ≥1.5×10\^9/L
  • AST and ALT ≤3× upper limit of normal (ULN)
  • Total bilirubin ≤1.5× ULN
  • Serum creatinine ≤1.5× ULN
  • No evidence of pneumonia on chest CT
  • Adequate cardiac function, defined as:
  • No myocardial ischemia on ECG
  • NYHA class I
  • LVEF ≥55% on echocardiogram
  • Normal cardiac markers (cTnI and BNP)
  • Normal thyroid function (T3, T4, FT3, FT4, TSH).
  • Willing and able to provide written informed consent.

Exclusion Criteria:

  • Male or inflammatory breast cancer.
  • Metastatic (Stage IV) breast cancer.
  • History of active autoimmune or inflammatory diseases requiring systemic treatment within the past 2 years (e.g., systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Hashimoto's thyroiditis). Exceptions: type I diabetes, hypothyroidism controlled with hormone replacement therapy, or skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis).
  • Concurrent other malignancies or history of other malignancies within the past 5 years (except adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix).
  • Any other serious non-malignant disease that may compromise compliance or place the patient at risk.
  • Major surgery within 4 weeks prior to study initiation or anticipated need for major surgery during the study.
  • Prior radiotherapy, chemotherapy, targeted therapy, endocrine therapy, or major surgery for breast cancer.
  • Known hypersensitivity to any component of the study drugs.
  • Poorly controlled cardiac disease (e.g., NYHA class II+ heart failure, unstable angina, myocardial infarction within the past year, or clinically significant arrhythmias requiring intervention).
  • History of interstitial lung disease (ILD), current ILD, or suspected ILD on imaging during screening.
  • Active infections, including:
  • HIV positive
  • Active tuberculosis
  • Active hepatitis B (HBV-DNA > 10\^3 IU/mL)
  • Active hepatitis C (HCV antibody positive with detectable HCV-RNA)
  • Active autoimmune disease requiring systemic treatment.
  • Dementia, significant intellectual impairment, or any psychiatric condition that impairs understanding of the informed consent.
  • Unhealed wounds, ulcers, or fractures within 4 weeks prior to signing consent; or any history of clinically significant bleeding or bleeding tendency.
  • Any other condition deemed by the investigator to be unsuitable for trial participation.

Quoted from ClinicalTrials.gov, NCT07394387, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07394387, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07394387